REVELATION BIOSCIENCES, INC.

Revelation Biosciences, Inc. (Nasdaq: REVB) is a clinical-stage biopharmaceutical company that reached public markets through a SPAC combination with Petra Acquisition Inc., which priced its IPO in 2021. The company is focused on developing innate immune system-based therapeutics targeting oncology and infectious disease indications. On May 7, 2026, Revelation Biosciences submitted an 8-K current report to the SEC under accession number 0001193125-26-212064, the latest in a series of public disclosures as the company continues to advance its pipeline within the competitive life sciences and biotechnology sector. Readers seeking full filing history, sponsor profiles, and ongoing SPAC analytics for REVB can sign up for access at SpacDesk.